120 related articles for article (PubMed ID: 8242542)
1. A phase II study of mitoxantrone combined with beta-interferon in unresectable hepatocellular carcinoma.
Colleoni M; Buzzoni R; Bajetta E; Bochicchio AM; Bartoli C; Audisio R; Bonfanti G; Nolè F
Cancer; 1993 Dec; 72(11):3196-201. PubMed ID: 8242542
[TBL] [Abstract][Full Text] [Related]
2. Hepatic arterial infusion of mitoxantrone in the treatment of primary hepatocellular carcinoma.
Shepherd FA; Evans WK; Blackstein ME; Fine S; Heathcote J; Langer B; Taylor B; Habal F; Kutas G; Pritchard KI
J Clin Oncol; 1987 Apr; 5(4):635-40. PubMed ID: 3031227
[TBL] [Abstract][Full Text] [Related]
3. Home treatment with interleukin 2 and beta-interferon in patients with colorectal cancer and hepatocellular carcinoma.
de Braud F; Colleoni M; Noli F; Bajetta E
Oncology; 1994; 51(5):472-6. PubMed ID: 8052492
[TBL] [Abstract][Full Text] [Related]
4. Combination therapy with transarterial chemoembolization and interferon-alpha compared with transarterial chemoembolization alone for hepatitis B virus related unresectable hepatocellular carcinoma.
Li M; Lu C; Cheng J; Zhang J; Cao C; Xu J; Xu J; Pan H; Zhong B; Tucker S; Wang D
J Gastroenterol Hepatol; 2009 Aug; 24(8):1437-44. PubMed ID: 19486255
[TBL] [Abstract][Full Text] [Related]
5. Intra-arterial chemotherapy followed by chemo-embolisation in unresectable hepatocellular carcinoma.
Colleoni M; Liessi G; Mastrapasqua G; Nelli P; Vicario G; Sgarbossa G; Pancheri F; Manente P
Eur J Cancer; 1997 Jan; 33(1):56-60. PubMed ID: 9071900
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of combination doxorubicin, interferon-alpha, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma.
Lu YS; Hsu C; Li CC; Kuo SH; Yeh KH; Yang CH; Hsu CH; Wu CY; Cheng AL
Hepatogastroenterology; 2004; 51(57):815-9. PubMed ID: 15143923
[TBL] [Abstract][Full Text] [Related]
7. Mitoxantrone in patients affected by hepatocellular carcinoma with unfavorable prognostic factors.
Colleoni M; Nole F; Di Bartolomeo M; de Braud F; Bajetta E
Oncology; 1992; 49(2):139-42. PubMed ID: 1315428
[TBL] [Abstract][Full Text] [Related]
8. No synergistic activity of epirubicin and interferon-alpha 2b in the treatment of hepatocellular carcinoma.
Bokemeyer C; Kynast B; Harstrick A; Laage E; Schmoll E; von Wussow P; Schmoll HJ
Cancer Chemother Pharmacol; 1995; 35(4):334-8. PubMed ID: 7828277
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy using 5-fluorouracil, mitoxantrone, and cisplatin for patients with advanced hepatocellular carcinoma: an analysis of 63 cases.
Yang TS; Chang HK; Chen JS; Lin YC; Liau CT; Chang WC
J Gastroenterol; 2004; 39(4):362-9. PubMed ID: 15168248
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of escalating dose mitoxantrone in combination with alpha-2-interferon in patients with advanced solid tumors.
Gasparini G; Dal Fior S; Pozza F; Panizzoni GA; Favretto S; Von Hoff DD
Invest New Drugs; 1991 Aug; 9(3):245-52. PubMed ID: 1783524
[TBL] [Abstract][Full Text] [Related]
11. Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy.
Leung TW; Tang AM; Zee B; Yu SC; Lai PB; Lau WY; Johnson PJ
Cancer; 2002 Jan; 94(2):421-7. PubMed ID: 11905412
[TBL] [Abstract][Full Text] [Related]
12. A phase II trial of continuous infusion of 5-fluorouracil, mitoxantrone, and cisplatin for metastatic hepatocellular carcinoma.
Ikeda M; Okusaka T; Ueno H; Takezako Y; Morizane C
Cancer; 2005 Feb; 103(4):756-62. PubMed ID: 15637692
[TBL] [Abstract][Full Text] [Related]
13. Study of local three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for patients with stage III hepatocellular carcinoma.
Li B; Yu J; Wang L; Li C; Zhou T; Zhai L; Xing L
Am J Clin Oncol; 2003 Aug; 26(4):e92-9. PubMed ID: 12902905
[TBL] [Abstract][Full Text] [Related]
14. Biochemical modulation of doxorubicin by high-dose tamoxifen in the treatment of advanced hepatocellular carcinoma.
Cheng AL; Yeh KH; Fine RL; Chuang SE; Yang CH; Wang LH; Chen DS
Hepatogastroenterology; 1998; 45(24):1955-60. PubMed ID: 9951847
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of mitoxantrone in unresectable primary hepatocellular carcinoma following hepatitis B infection.
Lai KH; Tsai YT; Lee SD; Ng WW; Teng HC; Tam TN; Lo GH; Lin HC; Lin HJ; Wu JC
Cancer Chemother Pharmacol; 1989; 23(1):54-6. PubMed ID: 2535794
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma.
Patt YZ; Hassan MM; Lozano RD; Brown TD; Vauthey JN; Curley SA; Ellis LM
J Clin Oncol; 2003 Feb; 21(3):421-7. PubMed ID: 12560429
[TBL] [Abstract][Full Text] [Related]
17. Chronic oral etoposide and tamoxifen in the treatment of far-advanced hepatocellular carcinoma.
Cheng AL; Chen YC; Yeh KH; Chuang SE; Chen BR; Chen DS
Cancer; 1996 Mar; 77(5):872-7. PubMed ID: 8608477
[TBL] [Abstract][Full Text] [Related]
18. A phase I-II trial of mitoxantrone by hepatic arterial infusion in patients with hepatocellular carcinoma or colorectal carcinoma metastatic to the liver.
Jones DV; Patt YZ; Ajani JA; Abbruzzese J; Carrasco CH; Charnsangavej C; Levin B; Wallace S
Cancer; 1993 Nov; 72(9):2560-3. PubMed ID: 8402476
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of mitoxantrone in patients with hepatocellular carcinoma.
Yoshida T; Okazaki N; Yoshino M; Ohkura H; Miyamoto K; Shimada Y
Eur J Cancer Clin Oncol; 1988 Dec; 24(12):1897-8. PubMed ID: 2851445
[No Abstract] [Full Text] [Related]
20. Phase II trial of mitoxantrone in head and neck carcinoma.
Sridhar KS; Hussein AM; Benedetto P; Waldman SM; Feun LG; Savaraj N; Richman SP; Ardalan B; Desai P
Am J Clin Oncol; 1991 Aug; 14(4):298-304. PubMed ID: 1650529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
